Background. After PCI for MI, angina has important implications on quality of life and healthcare utilization
|
|
- Vincent White
- 5 years ago
- Views:
Transcription
1 Angina Prevalence and Management for Myocardial Infarction Patients Treated with Percutaneous Coronary Intervention: Insights from the TRANSLATE-ACS Study Alexander C. Fanaroff, Lisa A. Kaltenbach, Eric D. Peterson, Connie N. Hess, David J. Cohen, Gregg C. Fonarow, Tracy Y. Wang on behalf of the TRANSLATE-ACS Investigators
2 Background After PCI for MI, angina has important implications on quality of life and healthcare utilization 1.5-fold increased risk of re-admission and repeat revascularization compared with patients without angina 2-fold increased risk of developing new depressive symptoms Lower self-perceived health and physical function Hess CN et al. Circulation. 2017;135: Maddox TM et al. Archives of Internal Medicine. 2008;168: Gardner AW et al. Angiology. 2011: Doll JA et al. Journal of the American Heart Association. 2016;5:e003205
3 Guideline Recommendations: A Stepped Approach Beta blocker + sublingual nitrate Class I, LOE B Calcium channel blocker or long-acting nitrate Class I, LOE B Ranolazine Class IIa, LOE A Revascularization Class I, LOE B Fihn et al ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease. Journal of the American College of Cardiology. 2012;60:e44-e164.
4 Objectives Describe longitudinal patterns of patientreported angina after PCI for MI Describe patterns of anti-angina medication usage among patients with self-reported angina after PCI for MI
5 Study design A contemporary, longitudinal observational study of patients with acute MI treated with PCI and P2Y 12 inhibitor therapy at > 200 hospitals from 2010 to 2012 Telephone interviews at 6 weeks, 6 months, and 12 months collected medications and Seattle Angina Questionnaire angina frequency SAQ angina frequency questions asks about frequency of angina symptoms and sublingual nitroglycerin use Responses summed to derive SAQ angina frequency score 100 = no angina; = monthly angina; = weekly angina; 0-39 = daily angina Spertus JA et al. Journal of the American College of Cardiology. 1995;25:
6 Patient population 12,365 patients enrolled in TRANSLATE-ACS 10,870 patients with evaluation of 6 week angina 3190 patients with stable angina for descriptive analysis of anti-anginal medication usage Died in-hospital (n = 14) Missing angina frequency at 6 weeks (n = 1,481) No angina at 6 weeks (n = 7,680)
7 Methods Report proportion of patients with 6-week angina with continued angina at 6 months and 12 months Report proportion of patients with angina taking nonbeta blocker (NBB) anti-anginal medications at 6 weeks, 6 months, and 12 months By angina frequency (monthly, daily/weekly) Among patients with persistent angina throughout follow-up Report proportion of patients with angina taking NBB anti-anginal medications at the time of repeat PCI
8 Baseline characteristics Demographics and Medical History Age (median) 57 Female sex 31.9% Black/African American 11.2% No insurance 18.0% Diabetes 26.0% Multivessel CAD 48.8% Cerebrovascular disease 7.7% Peripheral vascular disease 6.4% Details of Index MI and PCI STEMI 57.1% Multi-vessel disease 48.8% Discharge medications P2Y 12 inhibitor 99.5% Statin 95.3% Aspirin 98.7% ACEI/ARB 73.5% Beta blocker 93.6%
9 Proportion of patients Angina prevalence after PCI for MI 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 3% 18% 40% 79% 33% 6 weeks 6 months 12 months Time from index MI Monthly Weekly Daily
10 Percentage of patients Beta blocker usage 100% 90% 80% 90% 86% 82% 70% 60% 50% 40% 30% 20% 10% 0% 6 weeks 6 months 12 months
11 % of patients taking NBB antiangial medications NBB anti-angina medication usage CCB+Nitrate+Ran 30 Nitrate+Ran % 22% 23% CCB+Ran CCB+Nitrate 15 Ranolazine alone weeks 6 months 12 months Long-acting nitrate alone Calcium channel blocker alone
12 % with angina taking NBB anti-anginal NBB anti-anginal medication usage by angina severity % 16% 34% 18% 38% 22% Number of non-beta blocker antianginals Three Two One Daily/weekly Monthly Daily/weekly Monthly Daily/weekly Monthly 6 weeks 6 months 12 months Angina Frequency by time elapsed from MI
13 Persistent angina 1056 (33%) of 3190 patients with 6-week angina had angina for the entirety of 12 months follow-up 727 of 1056 (69%) never took a NBB antiangina medication 61% of patients with daily/weekly angina at 12 months
14 Anti-anginal medication usage and repeat PCI 381 of 3190 patients with 6 week angina had repeat PCI after 6 weeks through the end of follow-up 99 (26%) of 381 were prescribed a NBB antiangina medication at the time of PCI 19% taking 1 NBB medication 6% taking 2 NBB medications 1% taking 3 NBB medications
15 Limitations Analysis limited to patient-reported angina; unclear whether these patients have objective myocardial ischemia that would benefit from anti-angina medications Did not capture exercise frequency or tolerance, and it is possible that patients reporting angina are actually more active than those that did not Do not report on outcomes related to anti-angina medication usage; any outcomes analysis would be limited by confounding by indication
16 Conclusions Angina is present at 6 weeks in ~ 40% of patients undergoing PCI for MI and a substantial proportion continue to have angina at 12 months Non-beta blocker anti-angina medications are used infrequently in this patient population, even among those with more severe/persistent angina, and those undergoing PCI for continued angina symptoms Strategies to improve clinician recognition and treatment of angina symptoms are needed
17 Thank you
10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice
10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice Ajar Kochar, MD on behalf of: Anita Y. Chen, Puza P. Sharma, Neha J. Pagidipati, Gregg C. Fonarow, Patricia
More informationIschemic Heart Disease Interventional Treatment
Ischemic Heart Disease Interventional Treatment Cardiac Catheterization Laboratory Procedures (N = 11,61) is a regional and national referral center for percutaneous coronary intervention (PCI). A total
More informationMonth/Year of Review: November 2014 Date of Last Review: June 2012 PDL Classes: Anti-anginals, Cardiovascular
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More informationIschemic Heart Disease Interventional Treatment
Ischemic Heart Disease Interventional Treatment Cardiac Catheterization Laboratory Procedures (N = 89) is a regional and national referral center for percutaneous coronary intervention (PCI). A total of
More informationAffordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study
Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study Tracy Y. Wang, MD, MHS, MSc, FACC, FAHA presenting on behalf of ARTEMIS Investigators Guidelines DAPT
More informationCORONARY ARTERY DISEASE (CAD) MEASURES GROUP OVERVIEW
CONARY ARTERY DISEASE (CAD) MEASURES GROUP OVERVIEW 2014 PQRS OPTIONS F MEASURES GROUPS: 2014 PQRS MEASURES IN CONARY ARTERY DISEASE (CAD) MEASURES GROUP: #6. Coronary Artery Disease (CAD): Antiplatelet
More informationPCI for Stable Ischemic Heart Disease: What Happened in the Last Week?
PCI for Stable Ischemic Heart Disease: What Happened in the Last Week? Ajay J. Kirtane, MD, SM Center for Interventional Vascular Therapy Columbia University Medical Center / NewYork Presbyterian Hospital
More informationQuality of Life After Everolimus- Eluting Stents or Bypass Surgery for Treatment of Left Main Coronary Artery Disease:
Quality of Life After Everolimus- Eluting Stents or Bypass Surgery for Treatment of Left Main Coronary Artery Disease: Results from the EXCEL Trial Suzanne J. Baron MD MSC on behalf of the EXCEL Investigators
More informationThe ESC Registry on Chronic Ischemic Coronary Disease
EURObservational Research Programme The ESC Registry on Chronic Ischemic Coronary Disease Prof. Fausto J. Pinto, FESC, FACC, FASE, FSCAI Immediate Past-President, ESC University Hospital Sta Maria University
More informationScreening for Asymptomatic Coronary Artery Disease: When, How, and Why?
Screening for Asymptomatic Coronary Artery Disease: When, How, and Why? Joseph S. Terlato, MD FACC Clinical Assistant Professor, Brown Medical School Coastal Medical Definition The presence of objective
More informationAnginal pain is a result of an imbalance between myocardial oxygen supply and demand. Pharmacological management is aimed at prevention of myocardial
Angina Anginal pain is a result of an imbalance between myocardial oxygen supply and demand. Pharmacological management is aimed at prevention of myocardial ischemia and pain as well as prevention of myocardial
More informationSupplementary Material to Mayer et al. A comparative cohort study on personalised
Suppl. Table : Baseline characteristics of the patients. Characteristic Modified cohort Non-modified cohort P value (n=00) Age years 68. ±. 69.5 ±. 0. Female sex no. (%) 60 (0.0) 88 (.7) 0.0 Body Mass
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationMedical Management of Acute Coronary Syndrome: The roles of a noncardiologist. Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI
Medical Management of Acute Coronary Syndrome: The roles of a noncardiologist physician Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI Outcome objectives of the discussion: At the end of the
More informationCoronary Catheterization and Percutaneous Coronary Intervention in China 10-Year Results From the China PEACE-Retrospective CathPCI Study
Coronary Catheterization and Percutaneous Coronary Intervention in China 10-Year Results From the China PEACE-Retrospective CathPCI Study Xin Zheng, MD, PhD; Jeptha P. Curtis, MD; Shuang Hu, PhD; YongfeiWang,
More informationTreatment Options for Angina
Treatment Options for Angina Interventional Cardiology Perspective Michael A. Robertson, M.D. 10/30/10 Prevalence of CAD in USA 15 million Americans with CAD 2 million diagnostic catheterizations 1 million
More informationStable Ischemic Heart Disease. Ivan Anderson, MD RIHVH Cardiology
Stable Ischemic Heart Disease Ivan Anderson, MD RIHVH Cardiology Outline Review of the vascular biology of atherosclerosis Why not just cath everyone with angina? Medical management of ischemic cardiomyopathy
More information2/17/2010. Grace Lin, MD Assistant Professor of Medicine University of California, San Francisco
Modern Management of Patients with Stable Coronary Artery Disease Grace Lin, MD Assistant Professor of Medicine University of California, San Francisco Scope of the Problem Prevalence of CAD: 17.6 million
More informationSTEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology
STEMI update Vijay Krishnamoorthy M.D. Interventional Cardiology OVERVIEW Current Standard of Care in Management of STEMI Update in management of STEMI Pre-Cath Lab In the ED/Office/EMS. Cath Lab Post
More informationLack of Effect of Beta-blocker Therapy in Patients with ST-elevation Acute Myocardial Infarction in PCI Era
Lack of Effect of Beta-blocker Therapy in Patients with ST-elevation Acute Myocardial Infarction in PCI Era B. Bao 1, N. Ozasa 1, T. Morimoto 2, Y. Furukawa 3, M. Shirotani 4, H. Ogawa 5, C. Tei 6, H.
More informationEfficacy of Ranolazine in Patients With Chronic Angina
Journal of the American College of Cardiology Vol. 53, No. 17, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.01.037
More informationUnstable Angina: Relationship of Clinical Presentation, Coronary Artery Pathology, and Clinical Outcome
~~~ ~ Clin. Cardiol. 16, 6-122 (1993) Unstable Angina: Relationship of Clinical Presentation, Coronary Artery Pathology, and Clinical Outcome BARRY D. Bmm, M.D., JAY DINERMAN, M.D., RALP HARTKE, JR., M.D.,
More informationTiming of Surgery After Percutaneous Coronary Intervention
Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet
More informationManagement of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018
Management of Stable Ischemic Heart Disease Vinay Madan MD February 10, 2018 1 Disclosure No financial disclosure. 2 Overview of SIHD Diagnosis Outline of talk Functional vs. Anatomic assessment Management
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Cohen DJ, Van Hout B, Serruys PW, et al. Quality of life after
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationAcute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine
Acute Coronary Syndrome Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Topics Timing is everything So many drugs to choose from What s a MINOCA? 2 Acute
More informationCardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate.
Complete the following. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate. 2. drugs affect the force of contraction and can be either positive or negative. 3.
More information2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease Developed in Collaboration with American Association for Thoracic Surgery, American
More informationPerioperative Cardiology Consultations for Noncardiac Surgery Ischemic Heart Disease
2012 대한춘계심장학회 Perioperative Cardiology Consultations for Noncardiac Surgery Ischemic Heart Disease 울산의대울산대학병원심장내과이상곤 ECG CLASS IIb 1. Preoperative resting 12-lead ECG may be reasonable in patients with
More informationRandomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial
Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial Embargoed until 10:45 a.m. CT, Monday, Nov. 14, 2016 David
More informationSTATINS EVALUATION IN CORONARY PROCEDURES AND REVASCULARIZATION
STATINS EVALUATION IN CORONARY PROCEDURES AND REVASCULARIZATION Otávio Berwanger, MD, FACS - On behalf of the SECURE Steering Committee and Investigators Trial Organization Trial Steering Committee Dr.
More informationSTEMI AND MULTIVESSEL CORONARY DISEASE
STEMI AND MULTIVESSEL CORONARY DISEASE ΤΣΙΑΦΟΥΤΗΣ Ν. ΙΩΑΝΝΗΣ ΕΠΕΜΒΑΤΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ Α ΚΑΡΔΙΟΛΟΓΙΚΗ ΝΟΣ ΕΡΥΘΡΟΥ ΣΤΑΥΡΟΥ IRA 30-50% of STEMI patients have additional stenoses other than the infarct related
More informationThe Influence of Race on Health Status Outcomes One Year After an Acute Coronary Syndrome
Journal of the American College of Cardiology Vol. 46, No. 10, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.05.092
More informationApproach to Multi Vessel disease with STEMI
Approach to Multi Vessel disease with STEMI MANAGEMENT OF ST-ELEVATION MYOCARDIAL INFARCTION Dr. Thomas Alexander, M.D; D.M; F.A.C.C. Senior Consultant and Interventional Cardiologist Kovai Medical Centre
More informationCoronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Coronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide is based on the 2017 KP National Coronary Artery Disease
More informationQuality of Life Outcomes: The Trial to Assess Chelation Therapy
Quality of Life Outcomes: The Trial to Assess Chelation Therapy Daniel B. Mark, MD, MPH Professor of Medicine Director, Outcomes Research Duke University Medical Center Duke Clinical Research Institute
More informationPractice-Level Executive Summary Report
PINNACLE Registry Metrics 0003, Test Practice_NextGen [Rolling: 1st April 2015 to 31st March 2016 ] Generated on 5/11/2016 11:37:35 AM American College of Cardiology Foundation National Cardiovascular
More informationThe University of Mississippi School of Pharmacy
LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA Lokhandwala T. MS, Yang Y. PhD, Thumula V. MS, Bentley J.P.
More informationSupplementary Online Content
Supplementary Online Content Valle JA, Tamez H, Abbott JD, et al. Contemporary use and trends in unprotected left main coronary artery percutaneous coronary intervention in the United States: an analysis
More informationRevascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing
Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Evidence and Uncertainties Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine
More informationVersion 4.4. Institutional Outcomes Report 2014Q3. National Outcomes Report Aggregation Date: Jan 12, :59:59 PM
Version 4.4 Institutional Outcomes Report 2014Q3 National Outcomes Report 999997 Aggregation Date: Jan 12, 2015 11:59:59 PM Publish Date: Jan 29, 2015 If User desires to publish or otherwise distribute
More informationAbstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
More informationCulprit PCI vs MultiVessel PCI for Acute Myocardial Infarction
Culprit PCI vs MultiVessel PCI for Acute Myocardial Infarction Dipti Itchhaporia, MD, FACC, FESC Trustee, American College of Cardiology Director of Disease Management, Hoag Hospital Robert and Georgia
More informationNon ST Elevation-ACS. Michael W. Cammarata, MD
Non ST Elevation-ACS Michael W. Cammarata, MD Case Presentation 65 year old man PMH: CAD s/p stent in 2008 HTN HLD Presents with chest pressure, substernally and radiating to the left arm and jaw, similar
More informationQuestions and Answers: The NIH Trial of EDTA Chelation Therapy for Coronary Heart Disease
Questions and Answers: The NIH Trial of EDTA Chelation Therapy for Coronary Heart Disease Results from the Trial to Assess Chelation Therapy will be published in the Journal of the American Medical Associatio
More informationPreoperative Cardiac Risk Assessment: Approach & Guidelines
Preoperative Cardiac Risk Assessment: Approach & Guidelines By, Liam Morris, MD., FACC (02/03/18) CPG : Clinical Practice Guidelines GDMT : Guidelines Directed Medical Therapy GWC : Guideline Writing Committee
More informationAcute Coronary Syndrome
Acute Coronary Syndrome Clinical Manifestation of CAD Silent Ischemia/asymptomatic Stable Angina Acute Coronary Syndrome (Non- STEMI/UA and STEMI) Arrhythmias Heart Failure Sudden Death Pain patterns with
More informationCase Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)?
Cronicon OPEN ACCESS CARDIOLOGY Case Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)? Valentin Hristov* Department of Cardiology, Specialized
More informationRanolazine Reduces Patient-Reported Angina Severity and Frequency and Improves Quality of Life in Selected Patients with Chronic Angina
Drugs R D (2013) 13:207 213 DOI 10.1007/s40268-013-0026-4 ORIGINAL RESEARCH ARTICLE Ranolazine Reduces Patient-Reported Angina Severity and Frequency and Improves Quality of Life in Selected Patients with
More informationMid-term results from real-world REPARA registry. Felipe Hernandez, on behalf of the REPARA investigators
Mid-term results from real-world REPARA registry Felipe Hernandez, on behalf of the REPARA investigators Potential conflicts of interest Speaker's name: Felipe Hernandez I have the following potential
More informationRanolazine: An Update
Ranolazine: An Update J. Dawn Abbott, M.D., F.A.C.C., F.S.C.A.I. Director, Interventional Cardiology Fellowship Associate Professor of Medicine Brown Medical School Cardiovascular Institute Outline Ranolazine
More informationSafety and Efficacy of the Coronary Sinus Reducer in Patients with Refractory Angina: the COSIRA Trial
Safety and Efficacy of the Coronary Sinus Reducer in Patients with Refractory Angina: the COSIRA Trial (COronary SInus Reducer for Treatment of Refractory Angina) Stefan Verheye, MD Cardiovascular Center,
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationCan Angioplasty Improve Quality of Life for CAD Patients?
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/can-angioplasty-improve-quality-of-life-for-cadpatients/4000/
More informationProgram Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name
Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for, Atrial Fibrillation, Hypertension and.
More informationPatient Navigator Program: Focus MI Diplomat Hospital Metrics
Patient Navigator Program: Focus MI Diplomat Hospital Metrics Goal Statement: To reduce avoidable hospital readmissions for patients discharged with acute myocardial infarction (AMI) by supporting a culture
More informationOff-Label Disclaimer
Off-Label Disclaimer Slides that include contain data that is not within the FDA approved package insert and have not otherwise been approved by the FDA 1 ASSESSMENT AND TREATMENT GOALS OF CHRONIC ANGINA
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationType of intervention Treatment. Economic study type Cost-effectiveness analysis.
The impact of acute coronary syndrome on clinical, economic, and cardiac-specific health status after coronary artery bypass surgery versus stent-assisted percutaneous coronary intervention: 1-year results
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationAppropriateness of Percutaneous Coronary Interventions in Washington State
Appropriateness of Percutaneous Coronary Interventions in Washington State Steven M. Bradley, Charles Maynard, Chris L. Bryson VA Puget Sound Healthcare System and University of Washington Presenter Disclosure
More informationConsensus Core Set: Cardiovascular Measures Version 1.0
Consensus Core Set: Cardiovascular s NQF 0330 Hospital 30-day, all-cause, riskstandardized readmission rate (RSRR) following heart failure hospitalization 0229 Hospital 30-day, all-cause, riskstandardized
More information4. Which survey program does your facility use to get your program designated by the state?
STEMI SURVEY Please complete one survey for each TCD designation you have in your facility. There would be a maximum of three surveys completed if your facility was designated as a trauma, stroke and STEMI
More informationSEX DIFFERENCES IN HEALTH STATUS AFTER ACUTE MYOCARDIAL INFARCTION BY ANNE NZUKI
SEX DIFFERENCES IN HEALTH STATUS AFTER ACUTE MYOCARDIAL INFARCTION BY ANNE NZUKI Submitted to the graduate degree program in Clinical Research and the Graduate Faculty of the University of Kansas in partial
More informationAcute Coronary Syndromes
Overview Acute Coronary Syndromes Rabeea Aboufakher, MD, FACC, FSCAI Section Chief of Cardiology Altru Health System Grand Forks, ND Epidemiology Pathophysiology Clinical features and diagnosis STEMI management
More informationPatrick W. Serruys MD. PhD. 1 Bernard Chevalier MD. 2 Yoshinobu Onuma MD. PhD. 3 on behalf of ABSORB II investigators
TCT 216, Washington convention center October 3 th 216, 8:3 am- Room 159 Level 1 Late breaking clinical trial and First report investigations Press Conf.1 ABSORB II: Three-year Clinical Outcomes from a
More informationAPPENDIX F: CASE REPORT FORM
APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more
More informationRomualdo Belardinelli, MD, FESC Cardiovascular Sciences Department, Lancisi Heart Institute, AOR Ancona, Italy
Original Article Heart Metab. (2017) 73:13-17 Treating myocardial ischemia in diabetics: drugs, surgery, and stents Romualdo Belardinelli, MD, FESC Cardiovascular Sciences Department, Lancisi Heart Institute,
More informationLow Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)
Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,
More informationA Comparative Study on the Effect of Ranolazine and Ivabradine on High Sensitivity C - reactive protein In Cardiac Patients
Human Journals Mini Review March 2017 Vol.:8, Issue: 4 All rights are reserved by Prof. Dr. Mathew George et al. A Comparative Study on the Effect of Ranolazine and Ivabradine on High Sensitivity C - reactive
More information2008, American Heart Association. All rights reserved.
AHA 2008 Cocaine-Associated Chest Pain and Myocardial Infarction Slide Set Based on the AHA 2008 Scientific Statement for Management of Cocaine-Associated Chest Pain and Myocardial Infarction George J.
More informationShould All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function?
Should All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function? Avi Shimony, MD, FESC Cardiology Division Soroka University Medical Center Ben-Gurion University, Beer-Sheva Disclosure
More information6/1/18 LEARNING OBJECTIVES PATIENT POPULATION PRESENTATIONS
PREVENTING HOSPITAL READMISSIONS IN CARDIOVASCULAR PATIENTS Christina Cortez Perry, MSN, FNP-C, CCCC Cardiology Coordinator- Corpus Christi Medical Center 1 2 LEARNING OBJECTIVES Identify the target patient
More informationJMSCR Vol 07 Issue 01 Page January 2018
www.jmscr.igmpublication.org Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v7i1.109 Short Term Outcome in a Severe Coronary Artery Disease with
More informationTHE BRIDGE-ACS TRIAL
A Multifaceted Intervention to Narrow the Evidence-Based Gap in the Treatment of Acute Coronary Syndromes: THE BRIDGE-ACS TRIAL Presenter: Otavio Berwanger (MD; PhD) on Behalf of the BRIDGE-ACS Steering
More informationLessons learned From The National PCI Registry
Lessons learned From The National PCI Registry w a v e On Behalf of The Publication Committee of the National PCI Registry Objectives & Anticipated Achievements To determine the epidemiology of patients
More informationCoronary Heart Disease. Iqbal Malik
Coronary Heart Disease Iqbal Malik Pathophysiology IHD Case chest pain Question -interactive What is the result of the exercise test? 1. negative 2. positive 3. equivocal 4. other Q2 answer STEMI! What
More informationCoronary Artery Disease: Revascularization (Teacher s Guide)
Stephanie Chan, M.D. Updated 3/15/13 2008-2013, SCVMC (40 minutes) I. Objectives Coronary Artery Disease: Revascularization (Teacher s Guide) To review the evidence on whether percutaneous coronary intervention
More informationΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΣΤΟ ΔΙΑΒΗΤΙΚΟ ΑΣΘΕΝΗ
ΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΣΤΟ ΔΙΑΒΗΤΙΚΟ ΑΣΘΕΝΗ Νίκος Μεζίλης MD, FESC Κλινική Άγιος Λουκάς Why diabetes is associated with restenosis endothelial dysfunction metabolic alterations accelerated platelet deposition
More information2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction Developed in Collaboration with American College of Emergency Physicians and Society for Cardiovascular Angiography and
More informationThe Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI
The Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI Interventional Cardiologist Cardiovascular Institute of the South Director of Cardiovascular Services St. Charles Parish
More informationTreatment of Stable Coronary Artery Disease Pharmacotherapy
Treatment of Stable Coronary Artery Disease Pharmacotherapy José López-Sendón Hospital Universitario La Paz. Madrid. Spain Conflict of interest: I will discuss off label use and/or investigational use
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction 1.1
More informationPerformance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set
Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer
More informationCLINICIAN INTERVIEW RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE. An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA
RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA Dr Lincoff is an interventional cardiologist and the Vice Chairman for Research
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationAppendix: ACC/AHA and ESC practice guidelines
Appendix: ACC/AHA and ESC practice guidelines Definitions for guideline recommendations and level of evidence Recommendation Class I Class IIa Class IIb Class III Level of evidence Level A Level B Level
More informationTransfer in D2B. Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland. The Problem
Transfer in D2B Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland The Problem NRMI-5: North Carolina, July 2003- June 2004 NC Nation Guidelines N 2,738 79,927
More informationImplementation of myocardial system of care in a rural area in Brazil using telecardiology
Implementation of myocardial system of care in a rural area in Brazil using telecardiology Prof. Antonio Luiz Pinho Ribeiro Research and Innovation Head, University Hospital Universidade Federal de Minas
More informationPatient characteristics Intervention Comparison Length of followup
ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing
More informationDIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN
DIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN Objectives Gain competence in evaluating chest pain Recognize features of moderate risk unstable angina Review initial management of UA and
More informationAbbreviated New Drug Evaluation: Ranolazine
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationJames M. Kirshenbaum, MD, FACC
James M. Kirshenbaum, MD, FACC Associate Professor of Medicine Harvard Medical School Co-Director, Clinical Cardiology Director, Acute Interventional Cardiology Brigham and Women s Hospital Boston, MA
More informationTreatment of T Angina reatment of By Ali Alalawi
Treatment of Angina By Ali Alalawi Determinants of Oxygen Demand Need to improve ratio of: Coronary blood flow / cardiac work Or Cardiac O2 Supply / Cardiac Requirement Coronary Circulation vs Other Circulation
More informationGuidelines PATHOLOGY: FATAL PERIOPERATIVE MI NON-PMI N = 25 PMI N = 42. Prominent Dutch Cardiovascular Researcher Fired for Scientific Misconduct
PATHOLOGY: FATAL PERIOPERATIVE MI NON-PMI N = 25 PMI N = 42 Preoperative, Intraoperative, and Postoperative Factors Associated with Perioperative Cardiac Complications in Patients Undergoing Major Noncardiac
More informationEarly discharge in selected patients after an acute coronary syndrome can it be safe?
Early discharge in selected patients after an acute coronary syndrome can it be safe? Glória Abreu, Pedro Azevedo, Carina Arantes, Catarina Quina-Rodrigues, Sara Fonseca, Juliana Martins, Catarina Vieira,
More informationDavid A. Orsinelli, MD, FACC, FASE Professor, Internal Medicine The Ohio State University Division of Cardiovascular Medicine Columbus, Ohio
1 STABLE ISCHEMIC HEART DISEASE: A NON-INVASIVE CARDIOLOGIST S PERSECTIVE 2018 Cardiovascular Course for Trainees and Early Career Physicians APRIL 20, 2018 David A. Orsinelli, MD, FACC, FASE Professor,
More informationST-elevation myocardial infarctions (STEMIs)
Guidelines for Treating STEMI: Case-Based Questions As many as 25% of eligible patients presenting with STEMI do not receive any form of reperfusion therapy. The ACC/AHA guidelines highlight steps to improve
More informationEnvironmental. Vascular / Tissue. Metabolics
Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood
More information